Scientists at The Wistar Institute have solved a longstanding puzzle in ovarian cancer treatment: why anti-estrogen therapy often fails even when tumors express the hormone receptor that should make ...
With the aim of restoring female hormone cycles for pediatric cancer survivors, a team of University of Michigan researchers ...
Postmenopausal patients with ovarian or endometrial cancer who received conjugated equine estrogen may have increased mortality rates. For patients with ovarian and endometrial cancer, receiving ...
An open, prospective, single arm, phase II study of cadonilimab (PD-1/CTLA-4 bispecific antibody) with neoadjuvant chemotherapy in patients with advanced ovarian cancer: Interim analysis from the ...
CHICAGO -- Use of conventional hormonal therapy for menopausal symptoms doubled the long-term risk of ovarian cancer and the risk of dying of the disease, according to an analysis of Women's Health ...
mRNA injections could reduce aggressive ovarian tumors by rescuing an often mutated gene in high-grade serous ovarian patients, according to a preclinical study. The most common form of ovarian cancer ...
The FDA grants fast track designation to PHST001, an antibody targeting CD24, for advanced platinum-resistant and platinum-sensitive ovarian cancer. I urge researchers to look into why side effects ...
Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non–Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial The ASTRRA trial highlights both the power ...
A small percentage of ovarian cancers are hereditary, driven by inherited mutations in genes such as BRCA1 and BRCA2. Most ovarian cancers are “sporadic,” however, meaning they are driven by mutations ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results